Updated: Cowen Starts Stemline Therapeutics (STML) at Outperform

(Updated at 11:30)

Cowen initiated coverage on Stemline Therapeutics (NASDAQ: STML) with an Outperform rating. Analyst Boris Peaker thinks orphan hematological provides an attractive opportunity.

"We believe there are numerous factors supporting our positive investment opinion on Stemline Therapeutics, including (1) BPDCN provides solid indication for platform validation; (2) 3rd-line AML represents a sizable market opportunity with potential for use in earlier treatment setting; (3) expansion in autoimmune indications provides tremendous upside; (4) SL-701 in GBM presents attractive risk/reward profile. We believe that STML's CSC targeting platform is currently being overlooked by the market. Should SL-401 demonstrate efficacy in BPDCN/AML, we believe CSC targeting therapies will become of interest to investors and make shares of STML attractive at its current valuation."

For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.

Shares of Stemline Therapeutics closed at $13.22 yesterday.

You May Also Be Interested In

• CSX (CSX) PT Raised to $46 at TD Cowen
• TD Cowen on The Simply Goods Group (SMPL): 'Strategy In Place, But A Long Road For The Inflection'
• Pepsico (PEP) PT Lowered to $145 at TD Cowen